publication date: Apr. 13, 2018

Whistleblower suit claims McKesson repackaged, sold cancer drug “overfill”

By Paul Goldberg

A whistleblower lawsuit alleges that McKesson Corp. had been repackaging cancer drugs and charging the federal and state governments for “overfill,” extra drug that is routinely put into vials by manufacturers.

Technically, overfill makes up for normal waste. However, in earlier cases, pharmaceutical companies and drug distributors have been accused of pooling overfill from the vials in “non-aseptic facilities,” administering these drugs to patients, and charging Medicare, Medicaid and other payers.

The whistleblower, or relator, in the case against McKesson is Omni Healthcare Inc., a company that operates hematology and oncology practices in east central Florida, and the action is brought on behalf of the federal Medicare program and the Medicaid programs of 30 states. However, federal and state governments haven’t intervened in the case.

McKesson denies the allegations.

The suit, filed in the U.S. District Court for the Eastern District of New York, claims that between 2001 and 2010, McKesson entities, which include the Oncology Therapeutics Network and US Oncology Inc., had pooled overfill “in non-aseptic facilities, with workers in non-aseptic clothing/gear,” placing drugs into plastic pre-filled syringes, which were then re-labeled, packaged and shipped out to oncology practices.

“The net result of the altered expiration dates was that … Continue reading Whistleblower suit claims McKesson repackaged, sold cancer drug “overfill”

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.